NEW YORK — Cytek Biosciences said on Wednesday that it has acquired the cell analysis business of Tonbo Biosciences.
Financial and other terms of the acquisition were not disclosed.
According to Cytek, which went public on the Nasdaq this summer in a $200 million IPO, the business unit includes a portfolio of research reagents for cell preparation, flow cytometry, molecular immunology, PCR, and cell culture covering application areas across immunology, apoptosis, and immunoprofiling.
Fremont, California-based Cytek said that the deal will help expand its flow cytometry capabilities in protein and cell analysis research and that Tonbo's reagents will complement its own line of cFluor full spectrum cytometry reagents.
Cytek has developed the Full Spectrum Profiling (FSP) cell analysis technology, which uses the entire spectrum of a fluorescent signal to achieve higher multiplexing and better sensitivity and is at the core of two instruments, called Aurora and Northern Lights.